Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

InnovaTV 204 Trial in Cervical Cancer: Study Design and Key Efficacy Results

November 1st 2021

Rebecca Arend, MD, MPH, reviews the study design and results from innovaTV 204, which tested tisotumab vedotin in previously treated, recurrent, or metastatic cervical cancer.

Evolving Therapy in Cervical Cancer: Tisotumab Vedotin’s Mechanism of Action

November 1st 2021

A historical perspective on the management of recurrent or metastatic cervical cancer, followed by expert insight on tisotumab vedotin’s mechanism of action.

Dr. Monk on Potential Shifts to Treatment Sequencing Strategies in Cervical Cancer

October 29th 2021

Bradley J. Monk, MD, FACS, FACOG, discusses potential shifts to treatment sequencing strategies in cervical cancer.

Recruitment to Phase 2 Trial Examining PDS0101 Triplet in HPV Cancers Temporarily Suspended

October 29th 2021

The clinical-stage immunotherapy company PDS Biotechnology Corporation has announced the temporary suspension of recruitment to the National Cancer Institute–led phase 2 trial, which is evaluating a novel triplet combination comprised of PDS0101 and 2 immunomodulating agents in patients with advanced human papillomavirus cancers.

Dr. Colombo on the Next Steps With Pembrolizumab in Cervical Cancer

October 28th 2021

Nicoletta Colombo, MD, PhD, discusses the next steps with pembrolizumab in cervical cancer.

Tisotumab Vedotin Displays Efficacy, Tolerability in Cervical Cancer

October 27th 2021

The accelerated approval of the tissue factor–directed antibody and microtubule inhibitor tisotumab vedotin-tftv bolsters the treatment portfolio for patients with recurrent metastatic cervical cancer.

Locally Advanced Cervical Cancer: Surgery and Standard of Care Therapy

October 27th 2021

Focusing on locally advanced cervical cancer, experts elucidate the role of surgery and standard of care therapy.

What is the Current Role of Biomarker Testing in Cervical Cancer?

October 27th 2021

The panel reflects on the current, optimal use of biomarker testing to guide the management of cervical cancer.

Agenus Withdraws BLA for Balstilimab in Metastatic Cervical Cancer

October 22nd 2021

The immuno-oncology company Agenus has made the decision to withdraw its biologic license application for the use of the PD-1 inhibitor balstilimab in patients with recurrent or metastatic cervical cancer who experienced disease progression on, or after, chemotherapy.

Role of HPV Vaccination and Screening to Prevent Cervical Cancer

October 20th 2021

A comprehensive review of the current paradigm for HPV vaccination and screening to prevent cervical cancer.

Understanding the Biology and Staging of Cervical Cancer

October 20th 2021

Experts provide a brief overview of cervical cancer, focusing on the driving biology and FIGO staging system.

Inguinofemoral Radiotherapy Represents Safe Alternative to Lymphadenectomy in Vulvar Cancer With Micrometastases

October 18th 2021

Inguinofemoral radiotherapy could potentially spare patients with vulvar cancer and sentinel node micrometastases from the morbidity of a lymphadenectomy.

FDA Approves Pembrolizumab Plus Chemo With or Without Bevacizumab for Frontline Cervical Cancer

October 13th 2021

The FDA has approved pembrolizumab for use in combination with chemotherapy, with or without bevacizumab, in patients with persistent, recurrent or metastatic cervical cancer whose tumors have a PD-L1 combined positive score of 1 or higher, as determined by an FDA-approved test.

Dr. O’Malley on the Rationale to Evaluate Balstilimab/Zalifrelimab in Cervical Cancer

October 6th 2021

David M. O'Malley, MD, discusses the rationale to evaluate the combination of balstilimab and zalifrelimab in cervical cancer.

Dr. Naumann on the Evolution of Immunotherapy in Endometrial Cancer

October 5th 2021

R. Wendel Naumann, MD, discusses the evolution of immunotherapy in endometrial cancer.

Monk Reviews Transformative KEYNOTE-826 Data in Cervical Cancer and Next Steps for Research

October 5th 2021

Bradley J. Monk, MD, FACS, FACOG, discusses the practice-changing data from KEYNOTE-826 examining pembrolizumab plus chemotherapy with or without bevacizumab and next steps for research in recurrent or metastatic cervical cancer.

Dr. Backes on Challenges Regarding Staging of Ovarian Germ Cell Tumors

September 28th 2021

Floor J. Backes, MD, discusses challenges regarding staging and treatment locations in ovarian germ cell tumors.

FDA Grants Priority Review to Cemiplimab for Advanced Cervical Cancer

September 28th 2021

The FDA has granted priority review to a supplemental biologics license application for the use of cemiplimab-rwlc in the treatment of patients with recurrent or metastatic cervical cancer whose disease progressed on, or after, chemotherapy.

Monk Talks Tisotumab Vedotin and Exciting ESMO Data in Cervical Cancer

September 23rd 2021

Dr. Monk discusses the significance of the FDA approval of tisotumab vedotin and notable research that was presented at the 2021 ESMO Congress in cervical cancer.

Dr. Coleman on the FDA Approval of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer

September 20th 2021

Robert L. Coleman, MD, FACOG, FACS, discusses the FDA approval of tisotumab vedotin in recurrent or metastatic cervical cancer.